Takeda to regulate peginesatide medication for treating anemia in CRF patients Affymax.

Azmi Nabulsi, M.D., M.P.H, president of Takeda Global Research & Development Center, Inc., U.S. Added, Anemia is definitely a common consequence of chronic kidney disease or chronic renal failing that can occur in individuals on dialysis. Our goal with peginesatide, upon acceptance, is to provide a new therapeutic option to the doctors and dialysis patients who are challenged with handling anemia connected with chronic renal failure. .. Affymax, Takeda to regulate peginesatide medication for treating anemia in CRF patients Affymax, Inc. and Takeda Pharmaceutical Firm Limited , today announced that following pre-New Drug Program discussions with the U.S. Meals and Drug Administration , the firms will progress with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure individuals on dialysis in the usa.AccentCare relocates corporate headquarters to Dallas AccentCare, among the nation’s leaders in home healthcare, is relocating it is corporate headquarters from Irvine, California, to Dallas, a move that may create locally more than 100 new jobs. Dallas Parkway, Dallas, 75287. Brian Griggs and Tom Dyer, general companions, handled the purchase for Crown Sterling, while Steve Jarvie, executive vice president, Jones Lang LaSalle-Americas, Inc., represented AccentCare. Related StoriesReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixApplying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi’This move provides new possibilities for growth and will enable AccentCare to continue providing the compassionate, quality look after which we have been known since our founding more than ten years ago,’ stated William ‘Biff’ Comte, CEO of AccentCare.